Piper Sandler Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $20
Solid Biosciences (SLDB) Gets a Buy From Piper Sandler
Chardan Capital Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $15
Buy Rating Justified for Solid Biosciences Amid Promising Gene Therapy Advances
Solid Biosciences Analyst Ratings
HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $16 Price Target
H.C. Wainwright Maintains Solid Biosciences(SLDB.US) With Buy Rating, Maintains Target Price $16
Buy Rating Affirmed for Solid Biosciences Amid Promising Early Data on SGT-003 DMD Therapy
Analysts Are Bullish on Top Healthcare Stocks: Viridian Therapeutics (VRDN), Solid Biosciences (SLDB)
Barclays Maintains Solid Biosciences(SLDB.US) With Buy Rating, Cuts Target Price to $15
Barclays Remains a Buy on Solid Biosciences (SLDB)
Analysts Offer Insights on Healthcare Companies: Envista Holdings (NVST), Solid Biosciences (SLDB) and Lexeo Therapeutics, Inc. (LXEO)
Solid Biosciences up 10% Following J.P. Morgan Upgrade
Solid Biosciences Analyst Ratings
JPMorgan Upgrades Solid Biosciences to Overweight From Neutral, Adjusts Price Target to $15 From $10
Piper Sandler Reiterates Overweight on Solid Biosciences, Maintains $20 Price Target
Solid Biosciences Analyst Ratings
Komo: Maintaining the Solid Biosciences (SLDB.US) rating, adjusted from neutral to neutral, and adjusted the target price from $12.00 to $10.00.
Solid Biosciences Analyst Ratings
JP Morgan Maintains Neutral on Solid Biosciences, Lowers Price Target to $10